Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.44 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.44 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24936781 | 0.82 | HSD17B10 (0.46) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL19478610 | 0.82 | MAPT (0.46) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL21142427 | 0.79 | MAPT (0.43) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL14682698 | 0.78 | MAPT (0.34) | MAPTKDM4EHSD17B10HIF1AMEN1 | |
| SCHEMBL16746076 | 0.74 | MAPT (0.43) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL13053110 | 0.73 | MAPT (0.38) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL762283 | 0.72 | MAPT (0.57) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL14661398 | 0.72 | KDM4E (0.57) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL13836503 | 0.72 | MAPT (0.57) | MAPTKDM4EHSD17B10HIF1AALDH1A1 | |
| SCHEMBL21895250 | 0.72 | TSHR (0.39) | MAPTKDM4EHSD17B10HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773052-B2 | Enamine compound and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-10-03 | — | — | US | disclosed |
| US-11773052-B2 | Enamine compound and use thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-10-03 | — | — | US | disclosed |
| EP-3735430-B1 | VINYLETHER-BASED POLYMER AS DIELECTRIC | CLAP CO LTD (KR) | 2023-09-13 | — | — | EP | disclosed |
| US-11690236-B2 | Patterning method for preparing top-gate, bottom-contact organic field effect transistors | CLAP CO., LTD. (KR) | 2023-06-27 | — | — | US | disclosed |
| US-11690236-B2 | Patterning method for preparing top-gate, bottom-contact organic field effect transistors | CLAP CO., LTD. (KR) | 2023-06-27 | — | — | US | disclosed |
| US-20230023961-A1 | MITE INFESTATION TREATMENT | VETO-PHARMA (FR) | 2023-01-26 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200087245-A1 | ENAMINE COMPOUND AND USE THEREOF | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2020-03-19 | — | — | US | disclosed |
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
| US-20080070890-A1 | Spirocyclic Azetidinone Compounds and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| WO-2007107373-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2007-09-27 | — | — | WO | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070890-A1 | Spirocyclic Azetidinone Compounds and Methods of Use Thereof | LIPC, ZDHHC20, PMP22 | MAPT 4018/4885KDM4E 2193/4885HSD17B10 37/4885 |
| US-20200087245-A1 | ENAMINE COMPOUND AND USE THEREOF | ENY2, AHR, PAH | MAPT 4323/4885KDM4E 3253/4885HSD17B10 348/4885 |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | MAPT 2522/4885KDM4E 100/4885HSD17B10 995/4885 |
| US-11773052-B2 | Enamine compound and use thereof | ENY2, AHR, PAH | MAPT 4323/4885KDM4E 3253/4885HSD17B10 348/4885 |
| US-20230023961-A1 | MITE INFESTATION TREATMENT | RHOA, NPEPPS, TUBA3E | MAPT 659/4885KDM4E 726/4885HSD17B10 2468/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | MAPT 45/4885KDM4E 3117/4885HSD17B10 1971/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | MAPT 3296/4885KDM4E 47/4885HSD17B10 1441/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | MAPT 3025/4885KDM4E 904/4885HSD17B10 3828/4885 |
| US-20080194625-A1 | TETRAHYDROQUINOLINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, OPRL1 | MAPT 1112/4885KDM4E 612/4885HSD17B10 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.